… ProQR Announces Results for the First Quarter of 2017 Key … Investigational new drug (IND) application for QR-110, ProQR’s lead program in ophthalmology, was cleared by the FDA … Usher syndrome. The Company announced that it will host an R&D Day on June 15 th in New York where Company executives …
… ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory … a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The … chaired by Gerard Platenburg, Chief Innovation Officer of ProQR, now consists of six members including: Drs. Art Levin, …
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… ProQR to Present at Two Investor Conferences in September … at 9:10am ET, Daniel de Boer, Chief Executive Officer of ProQR, will present at the Cantor Fitzgerald Global … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w